Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07269210 · ClinicalTrials.gov registry record · Phase 2
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
A Phase 2 study of Severe Hypertriglyceridemia, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT07269210 is a Phase 2 study of Severe Hypertriglyceridemia that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 60 participants, below the 418-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07269210, a Phase 2 study of Severe Hypertriglyceridemia, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Solbinsiran
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- Ark Clinical Research - Long Beach
- Catalina Research Institute, LLC - Montclair
- Valley Clinical Trials, Inc. - Northridge
Florida
- Northeast Research Institute - Downtown Office - Jacksonville
- Novera Clinical Research - Miami
- Inpatient Research Clinic - Miami Lakes
- Clinical Site Partners, LLC dba Flourish Research - Winter Park
Arizona
- Axsendo Clinical Research - Peak Heart & Vascular - Phoenix - Phoenix
- Synexus Clinical Research US, Inc./Orange Grove Family Practice - Tucson
New York
- Weill Cornell Medical College - New York
- Icahn School of Medicine at Mount Sinai - New York
Connecticut
- CMR of Greater New Haven, LLC - Hamden
Illinois
- Great Lakes Clinical Trials - Ravenswood - Chicago
Indiana
- Investigators Research Group - Brownsburg
Kentucky
- Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital - Covington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07269210
The ClinicalTrials.gov registry entry for NCT07269210 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 418-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (86% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07269210 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07269210 about?
NCT07269210 is a clinical study titled "A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia". The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.
What is the current status of trial NCT07269210?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-12-08. Estimated completion is 2027-08.
What conditions does trial NCT07269210 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT07269210?
The interventions under investigation include: Placebo (DRUG), Solbinsiran (DRUG).
Who is sponsoring clinical trial NCT07269210?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07269210 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
COMPLETED · Phase 2
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.